This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
I read with great interest the editorial1 regarding the prevalence of familial hypercholesterolemia (FH) in the United States and why the early recognition of this condition is so essential for the optimal management of individuals with the condition, in particular, because the PCSK9 monoclonal antibodies, alirocumab and evolocumab, were approved …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$20.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Article Tools
Share this Article
- Letter by Paton Regarding Article, “Knowing the Prevalence of Familial Hypercholesterolemia Matters”Permalink:
Related Articles
Cited By...
- No citing articles found.